Altered inflammation, paraoxonase-1 activity and HDL physicochemical properties in obese humans with and without Prader-Willi syndrome

DMM Disease Models and Mechanisms

Volumn 5, Issue 5, 2012, Pages 698-705

  Ferretti, Gianna ^a   Bacchetti, Tiziana ^a   Masciangelo, Simona ^a   Grugni, Graziano ^b   Bicchiega, Virginia ^b  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN; LIPID HYDROPEROXIDE;

ADULT; ARTICLE; BLOOD CHEMISTRY; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; LIPID BLOOD LEVEL; MALE; OBESITY; OXIDATIVE STRESS; PHYSICAL CHEMISTRY; PRADER WILLI SYNDROME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; ARYLDIALKYLPHOSPHATASE; BODY WEIGHT; C-REACTIVE PROTEIN; HUMANS; INFLAMMATION; LIPID PEROXIDES; LIPOPROTEINS, HDL; OBESITY; PRADER-WILLI SYNDROME;

EID: 84865506678     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.009209     Document Type: Article

References (69)

1. Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J. C., James, W. P. T., Loria, C. M. and Smith, Jr, S. C. (2009). Harmonizing the metabolic syndrome. A Joint Interim Statement of the International Diabetes Federation Task Force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120, 1640-1645.
2. Aviram, M., Rosenblat, M., Bisgaier, C. L., Newton, R. S., Primo-Parmo, S. L. and La Du, B. N. (1998). Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J. Clin. Invest. 101, 1581-1590. (Pubitemid 28198486)
3. Bajnok, L., Seres, I., Varga, Z., Jeges, S., Peti, A., Karanyi, Z., Juhasz, A., Csongradi, E., Mezosi, E., Nagy, E. V. et al. (2007). Relationship of endogenous hyperleptinemia to serum paraoxonase 1, cholesteryl ester transfer protein, and lecithin cholesterol acyltransferase in obese individuals. Metabolism 56, 1542-1549. (Pubitemid 47562505)
4. Barter, P. J., Nicholls, S., Rye, K. A., Anantharamaiah, G. M., Navab, M. and Fogelman, A. M. (2004). Antiinflammatory properties of HDL. Circ. Res. 95, 764-772. (Pubitemid 39390578)
5. Bastard, J. P., Maachi, M., Lagathu, C., Kim, M. J., Caron, M., Vidal, H., Capeau, J. and Feve, B. (2006). Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur. Cytokine Netw. 17, 4-12.
6. Bondia-Pons, I., Ryan, L. and Martinez, J. A. (2012). Oxidative stress and inflammation interactions in human obesity. J. Physiol. Biochem. In Press.
7. Borque, L., Bellod, L., Rus, A., Seco, M. L. and Galisteo- González, F. (2000). Development and validation of an automated and ultrasensitive immunoturbidimetric assay for C-reactive protein. Clin. Chem. 46, 1839-1842.
8. Bradford, M. A. (1976). Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254.
9. Butler, M. G., Bittel, D. C., Kibiryeva, N. and Garg, U. (2006). C-reactive protein levels in subjects with Prader-Willi syndrome and obesity. Genet. Med. 8, 243-248.
10. Caixàs, A., Giménez-Palop, O., Broch, M., Vilardell, C., Megía, A., Simón, I., Giménez-Pérez, G., Mauricio, D., Vendrell, J., Richart, C. et al. (2008). Adult subjects with Prader-Willi syndrome show more low-grade systemic inflammation than matched obese subjects. J. Endocrinol. Invest. 31, 169-175. (Pubitemid 351596979)
11. Cassidy, S. B. and Driscoll, D. J. (2009). Prader-Willi syndrome. Eur. J. Hum. Genet. 17, 3-13.
12. Chung, B. H., Segrest, J. P., Ray, M. J., Brunzell, J. D., Hokanson, J. E., Krauss, R. M., Beaudrie, K. and Cone, J. T. (1986). Single vertical spin density gradient ultracentrifugation. Methods Enzymol. 128, 181-209. (Pubitemid 16100892)
13. Dousset, N., Ferretti, G., Taus, M., Valdiguiè, P. and Curatola, G. (1994). Fluorescence analysis of lipoprotein peroxidation. Methods Enzymol. 233, 459-469. (Pubitemid 24177572)
14. Einfeld, S. L., Kavanagh, S. J., Smith, A., Evans, E. J., Tonge, B. J. and Taffe, J. (2006). Mortality in Prader-Willi syndrome. Am. J. Ment. Retard. 111, 193-198.
15. Faienza, M. F., Ventura, A., Lauciello, R., Crinò, A., Ragusa, L., Cavallo, L., Spera, S. and Grugni, G. (2011). Analysis of endothelial protein C receptor gene and metabolic profile in Prader-Willi syndrome and obese subjects. Obesity. doi: 10.1038/oby.2011.349.
16. Ferretti, G., Bacchetti, T., Menanno, F. and Curatola, G. (2004). Effect of genistein against copper-induced lipid peroxidation of human high density lipoproteins (HDL). Atherosclerosis 172, 55-61. (Pubitemid 38058601)
17. Ferretti, G., Bacchetti, T., Moroni, C., Savino, S., Liuzzi, A., Balzola, F. and Bicchiega, V. (2005). Paraoxonase activity in high-density lipoproteins: a comparison between healthy and obese females. J. Clin. Endocrinol. Metab. 90, 1728-1733. (Pubitemid 40464045)
18. Ferretti, G., Bacchetti, T., Nègre-Salvayre, A., Salvayre, R., Dousset, N. and Curatola, G. (2006). Structural modifications of HDL and functional consequences. Atherosclerosis 184, 1-7. (Pubitemid 41721062)
19. Ferretti, G., Bacchetti, T., Masciangelo, S. and Bicchiega, V. (2010a). Effect of homocysteinylation on high density lipoprotein physico-chemical properties. Chem. Phys. Lipids 163, 228-235.
20. Ferretti, G., Bacchetti, T., Masciangelo, S. and Bicchiega, V. (2010b). HDL-paraoxonase and membrane lipid peroxidation: a comparison between healthy and obese subjects. Obesity 18, 1079-1084.
21. Frost, L. D. (2004). Glucose assays revisited: experimental determination of the glucose concentration in honey. Chem. Educator 9, 239-241.
22. González-Chávez, A., Elizondo-Argueta, S., Gutiérrez-Reye, G. and León-Pedroza, J. I. (2011). Pathophysiological implications between chronic inflammation and the development of diabetes and obesity. Cir. Cir. 79, 209-216.
23. Goswami, B., Tayal, D., Gupta, N. and Mallika, V. (2009). Paraoxonase: a multifaceted biomolecule. Clin. Chim. Acta 410, 1-12.
24. Grugni, G., Crinò, A., Bosio, L., Corrias, A., Cuttini, M., De Toni, T., Di Battista, E., Franzese, A., Gargantini, L., Greggio, N. et al. (2008). The Italian National Survey for Prader-Willi syndrome: An epidemiologic study. Am. J. Med. Genet. A 146, 861-872. (Pubitemid 351499790)
25. Grugni, G., Crinò, A., Bertocco, P. and Marzullo, P. (2009). Body fat excess and stimulated growth hormone levels in adult patients with Prader-Willi syndrome. Am. J. Med. Genet. A 149, 726-731.
26. Hansson, G. K. and Libby, P. (2006). The immune response in atherosclerosis: a double-edged sword. Nat. Rev. Immunol. 6, 508-519. (Pubitemid 43980523)
27. Haqq, A. M., Muehlbauer, M. J., Newgard, C. B., Grambow, S. and Freemark, M. (2011). The metabolic phenotype of Prader-Willi syndrome (PWS) in childhood: heightened insulin sensitivity relative to body mass index. J. Clin. Endocrinol. Metab. 96, E225-E232.
28. Higdon, J. V. and Frei, B. (2003). Obesity and oxidative stress: a direct link to CVD? Arterioscler. Thromb. Vasc. Biol. 23, 365-367. (Pubitemid 36337206)
29. Holub, M., Zwiauer, K., Winkler, C., Dillinger-Paller, B., Schuller, E., Schober, E., Stöckler-Ipsiroglou, S., Patsch, W. and Strobl, W. (1999). Relation of plasma leptin to lipoproteins in overweight children undergoing weight reduction. Int. J. Obes. Relat. Metab. Disord. 23, 60-66. (Pubitemid 29008400)
30. Höybye, C. (2006). Inflammatory markers in adults with Prader-Willi syndrome before and during 12 months growth hormone treatment. Horm. Res. 66, 27-32.
31. Huen, K., Richter, R., Furlong, C., Eskenazi, B. and Holland, N. (2009). Validation of PON1 enzyme activity assays for longitudinal studies. Clin. Chim. Acta 402, 67-74.
32. James, R. W. and Deakin, S. P. (2004). The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity. Free Radic. Biol. Med. 37, 1986-1994. (Pubitemid 39491318)
33. Kannampuzha, J., Darling, P. B., Maguire, G. F., Donnelly, S., McFarlane, P., Chan, C. T. and Connelly, P. W. (2010). Paraoxonase 1 arylesterase activity and mass are reduced and inversely related to C-reactive protein in patients on either standard or home nocturnal hemodialysis. Clin. Nephrol. 73, 131-138.
34. Karbownik-Lewinska, M., Kokoszko, A., Lewandowski, K. C., Shalet, S. M. and Lewinski, A. (2008). GH replacement reduces increased lipid peroxidation in GH-deficient adults. Clin. Endocrinol. 68, 957-964. (Pubitemid 351703954)
35. Kokoszko, A., Lewinski, A. and Karbownik-Lewinska, M. (2008). The role of growth hormone and insulin-like growth factor I in oxidative processes. Endokrynol. Pol. 59, 496-501.
36. Koncsos, P., Seres, I., Harangi, M., Illyés, I., Józsa, L., Gönczi, F., Bajnok, L. and Paragh, G. (2010). Human paraoxonase-1 activity in childhood obesity and its relation to leptin and adiponectin levels. Pediatr. Res. 67, 309-313.
37. Kumon, Y., Suehiro, T., Ikeda, Y. and Hashimoto, K. (2003). Human paraoxonase-1 gene expression by HepG2 cells is downregulated by interleukin-1beta and tumor necrosis factor-alpha, but is upregulated by interleukin-6. Life Sci. 73, 2807-2815. (Pubitemid 37153355)
38. Lahrach, H., Ghalim, N., Taki, H., Kettani, A., Er-Rachdi, L., Ramdani, B. and Saïle, R. (2008). Serum paraoxonase activity, high-sensitivity C-reactive protein, and lipoprotein disturbances in end-stage renal disease patients on long-term hemodialysis. J. Clin. Lipidol. 2, 43-50. (Pubitemid 351258915)
39. Lopes-Virella, M. F., Virella, G., Evans, G., Malenkos, S. B. and Colwell, J. A. (1980). Immunonephelometric assay of human apolipoprotein AI. Clin. Chem. 26, 1205-1208. (Pubitemid 10083333)
40. Mackness, B. and Mackness, M. (2010). Anti-inflammatory properties of paraoxonase-1 in atherosclerosis. Adv. Exp. Med. Biol. 660, 143-151.
41. Mackness, B., Durrington, P., McElduff, P., Yarnell, J., Azam, N., Watt, M. and Mackness, M. (2003). Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 107, 2775-2279.
42. Mackness, B., Hine, D., Liu, Y., Mastorikou, M. and Mackness, M. (2004). Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. Biochem. Biophys. Res. Commun. 318, 680-683. (Pubitemid 38624207)
43. Mackness, B., Hine, D., McElduff, P. and Mackness, M. (2006). High C-reactive protein and low paraoxonase1 in diabetes as risk factors for coronary heart disease. Atherosclerosis 186, 396-401.
44. McGowan, M. W., Artiss, J. D., Stranberg, D. R. and Zak, B. A. (1983). A peroxidase coupled method for the colorimetric determination of serum triglycerides. Clin. Chem. 29, 538-542. (Pubitemid 13160770)
45. Monteiro, R. and Azevedo, I. (2010). Chronic inflammation in obesity and the metabolic syndrome. Mediators Inflamm. 2010, 1-10.
46. Murphy, A. J. and Woollard, K. J. (2010). High-density lipoprotein: a potent inhibitor of inflammation. Clin. Exp. Pharmacol. Physiol. 37, 710-718.
47. Nauck, M., Graziani, M. S., Bruton, D., Cobbaert, C., Cole, T. G. and Lefevre, F. (2000). Analytical and clinical performance of a detergent-based homogeneous LDL-cholesterol assay: a multicenter evaluation. Clin. Chem. 46, 506-514. (Pubitemid 30210721)
48. Negre-Salvayre, A., Dousset, N., Ferretti, G., Bacchetti, T., Curatola, G. and Salvayre, R. (2006). Antioxidant and cytoprotective properties of high-density lipoproteins in vascular cells. Free Radic. Biol. Med. 41, 1031-1040. (Pubitemid 44348872)
49. Nourooz-Zadeh, J. (1999). Ferrous ion oxidation in presence of xylenol orange for detection of lipid hydroperoxides in plasma. Methods Enzymol. 300, 58-62.
50. Nowak, M., Wielkoszynski, T., Marek, B., Kos-Kudla, B., Swietochowska, E., Sieminska, L., Karpe, J., Kajdaniuk, D., Glogowska-Szelag, J. and Nowak, K. (2010). Antioxidant potential, paraoxonase 1, ceruloplasmin activity and C-reactive protein concentration in diabetic retinopathy. Clin. Exp. Med. 10, 185-192.
51. Oswall, A. and Yeo, G. (2010). Leptin and the control of body weight: a review of its diverse central targets, signaling mechanisms, and role in the pathogenesis of obesity. Obesity 18, 221-229.
52. Parasassi, T., DeStasio, G., Ravagnan, G., Rusch, R. M. and Gratton, E. (1991). Quantitation of lipid phases in phospholipid vesicles by the generalized polarization of Laurdan fluorescence. Biophys. J. 60, 179-189.
53. Patel, S., Harmer, J. A., Loughnan, G., Skilton, M. R., Steinbeck, K. and Celermajer, D. S. (2007). Characteristics of cardiac and vascular structure and function in Prader- Willi syndrome. Clin. Endocrinol. 66, 771-777. (Pubitemid 47024261)
54. Podrez, E. A. (2010). Anti-oxidant properties of high-density lipoprotein and atherosclerosis. Clin. Exp. Pharmacol. Physiol. 7, 719-725.
55. Proto, C., Romualdi, D., Cento, R. M., Romano, C., Campagna, G. and Lanzone, A. (2007). Free and total leptin serum levels and soluble leptin receptors levels in two models of genetic obesity: the Prader-Willi and the Down syndromes. Metabolism 56, 1076-1080. (Pubitemid 47021171)
56. Ragbir, S. and Farmer, J. A. (2010). Dysfunctional high-density lipoprotein and atherosclerosis. Curr. Atheroscler. Rep. 12, 343-348.
57. Rock, W., Rosenblat, M., Miller-Lotan, R., Levy, A. P., Elias, M. and Aviram, M. (2008). Consumption of wonderful variety pomegranate juice and extract by diabetic patients increases paraoxonase 1 association with high-density lipoprotein and stimulates its catalytic activities. J. Agric. Food Chem. 56, 8704-8713.
58. Roeschlau, P., Bernt, E. and Gruber, W. A. (1974). Enzymatische bestimmung des gesamtcholesterins im serum. Clin. Chem. Clin. Biochem. 12, 226.
59. Säemann, M. D., Poglitsch, M., Kopecky, C., Haidinger, M., Hörl, W. H. and Weichhart, T. (2010). The versatility of HDL: a crucial anti-inflammatory regulator. Eur. J. Clin. Invest. 40, 1131-1143.
60. Scanu, A. M. and Edelstein, C. (2008). HDL: bridging past and present with a look at the future. FASEB J. 22, 4044-4054.
61. Thaler, J. P. and Schwartz, M. V. (2010). Minireview: Inflammation and obesity pathogenesis: the hypothalamus heats up. Endocrinology 151, 4109-4115.
62. Thomas-Moya, E., Gomez-Perez, Y., Fiol, M., Gianotti, M., Llado, I. and Proenza, A. M. (2008). Gender related differences in paraoxonase 1 response to high-fat diet-induced oxidative stress. Obesity 16, 2232-2238.
63. Van Lenten, B. J., Hama, S. Y., de Beer, F. C., Stafforini, D. M., McIntyre, T. M., Prescott, S. M., La Du, B. N., Fogelman, A. M. and Navab, M. (1995). Antiinflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J. Clin. Invest. 96, 2758-2767.
64. Viardot, A., Sze, L., Purtell, L., Sainsbury, A., Loughnan, G., Smith, E., Herzog, H., Steinbeck, K. and Campbell, L. V. (2010). Prader-Willi syndrome is associated with activation of the innate immune system independently of central adiposity and insulin resistance. J. Clin. Endocrinol. Metab. 95, 3392-3399.
65. Vincent, H. K. and Taylor, A. G. (2006). Biomarkers and potential mechanisms of obesity-induced oxidant stress in humans. Int. J. Obes. 30, 400-418.
66. Visser, M., Bouter, L. M., McQuillan, G. M. and Wener, M. H. (1999). Elevated Creactive protein levels in overweight and obese adults. JAMA 282, 2131-2135.
67. Warnick, G. R. and Wood, P. D. (1995). National Cholesterol Education Program recommendations for measurement of high-density lipoprotein cholesterol: executive summary. Clin. Chem. 41, 1427-1433.
68. Whittington, J. E., Holland, A. J., Webb, T., Butler, J., Clarke, D. and Boer, H. (2001). Population prevalence and estimated birth incidence and mortality rate for people with Prader-Willi syndrome in one UK Health Region. J. Med. Genet. 38, 792-798. (Pubitemid 33032939)
69. Zalesin, K. C., Franklin, B. A., Miller, W. M., Peterson, E. D. and McCullough, P. A. (2011). Impact of obesity on cardiovascular disease. Med. Clin. North Am. 95, 919-937.